Title |
Current perspectives on fetal and neonatal alloimmune thrombocytopenia – increasing clinical concerns and new treatment opportunities
|
---|---|
Published in |
International Journal of Women's Health, April 2017
|
DOI | 10.2147/ijwh.s90753 |
Pubmed ID | |
Authors |
Heidi Tiller, Anne Husebekk, Maria Therese Ahlen, Tor B Stuge, Bjørn Skogen |
Abstract |
Differences in platelet type between the fetus and the mother can lead to maternal immunization and destruction of the fetal platelets, a condition named fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is reported to occur in ~1 per 1,000 live born neonates. The major risk is intracranial hemorrhage in the fetus or newborn, which is associated with severe neurological complications or death. Since no countries have yet implemented a screening program to detect pregnancies at risk, the diagnosis is typically established after the birth of a child with symptoms. Reports on broader clinical impact have increased clinical concern and awareness. Along with new treatment options for FNAIT, the debate around antenatal screening to detect pregnancies at risk of FNAIT has been revitalized. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 56 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 10 | 18% |
Researcher | 7 | 13% |
Other | 5 | 9% |
Student > Doctoral Student | 4 | 7% |
Student > Ph. D. Student | 4 | 7% |
Other | 8 | 14% |
Unknown | 18 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 32% |
Biochemistry, Genetics and Molecular Biology | 5 | 9% |
Nursing and Health Professions | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Business, Management and Accounting | 1 | 2% |
Other | 5 | 9% |
Unknown | 22 | 39% |